Blind 2Stage [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2019-05-30 14:56 (2213 d 10:50 ago) – Posting: # 20306
Views: 9,191

Hi Nastia,

❝ But can you clarify me the meaning of blindness in BE trials?


You know its meaning. ;-)
Never seen ones, except for Health Canada:

2.4.2 Blinding
To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered.


That’s a funny idea if the products don’t look the same.

❝ […] it turns out that blinding may even worse the situation (5.01% vs 7.36%, TIE). It is connected with the unknown PE (cause for BLIND=TRUE s20s<-mses), but isn't it contrintuitive?


Yes and yes. Have a look at Figure 1 of Golkowski et al.*

❝ Can it be true for parallel design also? Suppose we want to make a blind interim analyses after first stage with N subjects and recalculate sample size on fixed GMR=0.95 if total CV would be greater than initial suggestion. Will it cause any inflation?


Possibly.

❝ How to estimate it?


Simulations… Might be tricky cause we have to think about unequal group sizes and/or variances.

BTW, do you remember Paola Coppola’s presentation at last year’s BioBridges?

[image]




Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
41 visitors (0 registered, 41 guests [including 11 identified bots]).
Forum time: 01:46 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5